Genetic susceptibility to tobacco-related cancer

被引:114
作者
Wu, XF
Zhao, H
Suk, R
Christiani, DC
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
genetic susceptibility; tobacco-related cancer; polymorphism; phenotype; risk assessment; clinical outcome;
D O I
10.1038/sj.onc.1207811
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although cigarette smoking is the dominant risk factor for several epithelial cancers, only a small fraction of individuals with tobacco exposure develop cancer. The underlying hypothesis is that genetic factors may render certain smokers more susceptible to cancer than others. Genetic alterations in critical regulatory pathways may predispose cells to carcinogenesis. These pathways include regulation of xenobiotic metabolism; control of genomic stability, including DNA repair mechanisms, cell-cycle checkpoints, apoptosis and telomere length; and control of microenvironmental factors, such as matrix metalloproteinases, inflammation and growth factors. In addition, epigenetic events, such as promoter hypermethylation and loss of imprinting, are also involved in carcinogenesis. In this review, we will summarize recent advances in genetic susceptibility to tobacco-related cancer. Emphasizing on risk assessment, we will describe how genetic variations in the above-mentioned genetic pathways modify the tobacco-related cancer risk. In addition, we will discuss how genetic variations may assist in predicting clinical outcome, such as the natural history of cancer and treatment response. The measurements of genetic susceptibility by both genotypic and phenotypic assays are covered in the text. Finally, we present a number of current concerns that need to be addressed as the exciting field of molecular cancer epidemiology advances rapidly.
引用
收藏
页码:6500 / 6523
页数:24
相关论文
共 290 条
[91]  
Hung HC, 1997, CANCER EPIDEM BIOMAR, V6, P901
[92]   CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers:: a pooled analysis [J].
Hung, RJ ;
Boffetta, P ;
Brockmöller, J ;
Butkiewicz, D ;
Cascorbi, I ;
Clapper, ML ;
Garte, S ;
Haugen, A ;
Hirvonen, A ;
Anttila, S ;
Kalina, I ;
Le Marchand, L ;
London, SJ ;
Rannug, A ;
Romkes, M ;
Salagovic, J ;
Schoket, B ;
Gaspari, L ;
Taioli, E .
CARCINOGENESIS, 2003, 24 (05) :875-882
[93]   NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese [J].
Inatomi, H ;
Katoh, T ;
Kawamoto, T ;
Matsumoto, T .
INTERNATIONAL JOURNAL OF UROLOGY, 1999, 6 (09) :446-454
[94]  
Ishibe N, 1997, CANCER EPIDEM BIOMAR, V6, P1075
[95]  
Jeng YL, 2003, ANTICANCER RES, V23, P5149
[96]   P53 - THE PROMISING STORY CONTINUES TO UNFOLD [J].
JENSEN, RA ;
PAGE, DL .
HUMAN PATHOLOGY, 1993, 24 (05) :455-456
[97]   Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer [J].
Jeon, HS ;
Kim, KM ;
Park, SH ;
Lee, SY ;
Choi, JE ;
Lee, GY ;
Kam, S ;
Park, RW ;
Kim, IS ;
Kim, CH ;
Jung, TH ;
Park, JY .
CARCINOGENESIS, 2003, 24 (10) :1677-1681
[98]   Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1:: Implications for premenopausal breast cancer risk [J].
Jernström, H ;
Chu, M ;
Vesprini, D ;
Tao, YZ ;
Majeed, N ;
Deal, C ;
Pollak, M ;
Narod, SA .
MOLECULAR GENETICS AND METABOLISM, 2001, 72 (02) :144-154
[99]  
Johns LE, 2000, ENVIRON MOL MUTAGEN, V36, P221, DOI 10.1002/1098-2280(2000)36:3<221::AID-EM5>3.0.CO
[100]  
2-Q